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ABSTRACT 
Lycium barbarum has been used as a traditional Chinese medicine to nourish liver, 
kidneys and the eyes. However, the underlying mechanisms of its hepatic-protective 
properties remain uncertain. In this study, we aimed to investigate whether 
thioredoxin-interacting protein (TXNIP) and NOD-like receptor 3 (NLRP3) 
inflammasome mediated the attenuation of ethanol-induced hepatic injury by Lycium 
barbarum polysaccharide (LBP). Rat normal hepatocyte line BRL-3A was pre-treated 
with LBP prior to ethanol incubation. Hepatic damages, including apoptosis, 
inflammation, and oxidative stress, were measured. Then the inhibition of endogenous 
TXNIP expression was achieved by using its specific siRNA to test its possible 
involvement in the injury attenuation. We found that 50 μg/ml LBP pre-treatment 
significantly alleviated 24-h ethanol exposure-induced overexpression of TXNIP, 
increased cellular apoptosis, secretion of inflammatory cytokines, activation of 
NLRP3 inflammasome, production of ROS, and reduced antioxidant enzyme 
expression. Silence of TXNIP suppressed the activated NLRP3 inflammasome, 
increased oxidative stress and worsened apoptosis in the cells. Further addition of 
LBP did not influence the effects of TXNIP inhibition on the cells. In conclusion, 
inhibition of hepatic TXNIP by LBP contributes to the reduction of cellular apoptosis, 
oxidative stress and NLRP3 inflammasome-mediated inflammation.  
Keywords: LBP; TXNIP; NLRP3 inflammasome  
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1. Introduction 
    Alcoholic liver disease (ALD) encompasses a spectrum of hepatic injuries, 
ranging from steatosis to cirrhosis. The abuse of alcohol remains a major health and 
social burden all over the world. In the developed world, alcohol-related disease 
accounts for as much as 9.2% of all disability-adjusted life years [1]. Chronic 
over-consumption of alcohol induces steatosis, which occurs in more than 90% of 
heavy drinkers [2]. Advanced alcoholic fatty liver disease (steatohepatitis), fibrosis, 
and even hepatocellular carcinoma (HCC) may progress from prolonged alcohol 
consumption. To date, although several key events during the development of ALD 
have been identified, the detailed pathologic mechanisms of the disease and its 
interactions with other risk factors (e.g. age, obesity, and smoking) still remain elusive 
[3]. Among these characterized mechanisms, increased hepatic inflammation and 
oxidative stress are thought to play critical roles in the development of ALD [4, 5].  
    Inflammasomes are a group of large caspase-1-activating protein complexes in 
response to the evoke of innate immunity and production of pro-inflammatory 
cytokines, including NLRP3, NLRC4, AIM2 and NLRP6 inflammasomes [6]. They 
sense pathogen-associated molecular patterns (PAMPs) in the cytosol as well as the 
host-derived signals known as damage-associated molecular patterns (DAMPs) [7]. 
Inflammasomes, particularly NLRP3 inflammasome, are shown to be activated in a 
variety of liver diseases, including drug-induced liver injury [8], ischemia–reperfusion 
injury [9], endotoxin-induced liver injury and cholestasis [10, 11], viral hepatitis [12], 
fibrosis [13], and non-alcoholic fatty liver disease [14, 15]. However, to date, little is 
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known about the role of inflammasome in the pathogenesis of ALD. 
    Oxidative stress is another vital contributor to the development of ALD. It is 
shown that acute and chronic ethanol treatments increase the production of reactive 
oxygen and nitrogen species (ROS/RNS) while decrease cellular antioxidant defenses 
levels. Increased oxidative stress may cause lipid peroxidation, inflammation, 
apoptosis, and necrosis in the liver, forming a positive feedback loop which 
significantly aggravates the ALD severity [16]. One of the promoters of hepatic 
oxidative stress is thioredoxin-interacting protein (TXNIP), which can inhibit 
thioredoxins (Trx)-1 and -2 in the cytosol and mitochondria, respectively [17, 18]. 
TXNIP is found to be a promising therapeutic target in hepatic ischemia–reperfusion 
injury [19], hyperglycemia [20], acute liver failure [21], and HCC [22]. Interestingly, 
a recent study found that TXNIP links oxidative stress to inflammasome activation 
[23]. 
    In clinic, treatment options for ALD are limited. Abstinence is the most 
important therapeutic intervention for patients. It has been demonstrated to 
significantly improve clinical outcomes and even to reverse fatty liver [24]. 
Nutritional support with herbal supplements receives mass attention in the past decade 
because this therapy is shown to reduce the severity of ALD both in basic studies and 
clinical trials [25]. In the current study, we firstly tested the protective effects of 
lycium barbarum polysaccharide (LBP), a proven hepatoprotective agent from 
Traditional Chinese medicine in an in vitro ALD model. The involvement of TXNIP 
and NLRP3 inflammasome were then characterized.  
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2. Materials and methods 
2.1. Chemicals and reagents 
The preparation for LBP extracts was the same as reported previously [26]. All 
cell culture consumables and reagents were bought from either Corning Incorporated 
(Corning, NY) or Gibco (Carlsbad, CA). Antibodies against catalase (CAT), 
glutathione peroxidase 1 (GPx1), NLRP3, and caspase-1 were bought from Abcam 
(Cambridge, England). ASC and TXNIP antibodies were purchased from Enzo Life 
Sciences (Farmingdale, NY) and Santa Cruz Biotechnology (Santa Cruz, CA), 
respectively. Pure ethanol was from Guangzhou Chemical Reagent Factory 
(Guangzhou, China). 
 
2.2. Cell culture and treatments 
Rat normal hepatocyte BRL-3A cell line was supplied by the Cell Bank of Type 
Culture Collection of Chinese Academy of Sciences (Shanghai, China). It was 
cultured in DMEM with 10% (v/v) FBS at 37 °C with 5% CO2 using a cell incubator. 
Before every treatment, cells must reach a confluence of 60-70%. For the 
pre-treatment with LBP, PBS dissolved LBP was added 2 hours before the ethanol 
treatment. 
For the small interfering RNA (siRNA) assay, BRL-3A cells were transiently 
transfected with 100 nM control siRNA or TXNIP siRNA (GenePharma, Shanghai, 
China) using Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA), according to the 
instructions from manufacturer [27]. After 48 hours, the efficiency of siRNA silencing 
6 
 
was measured by quantitative PCR. The sequences of TXNIP siRNA and PCR 
primers were listed in Table 1. 
 
2.3. MTT assay 
Cell viability was evaluated by the conversion of 
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma-Aldrich, 
St. Louis, MO) to a purple color product by cellular mitochondria. After drug 
treatment, cells from each group were washed by sterile PBS 3 times and then 
incubated with 5 mg/ml MTT for 3 hrs, and subsequently dissolved in dimethyl 
sulfoxide (DMSO). The absorbance of MTT was measured at 570 nm. 
 
2.4. Quantification of apoptotic cells 
After drug treatment, Hoechst 33342 (5 μg/ml) and propidium iodide (5 μg/ml) 
were added to each well to stain live cells. The results were expressed as the 
percentage of apoptosis (PA): PA = apoptotic cell number/ total cell number × 100% 
[28]. 
 
2.5. Measurement of ROS production 
Intracellular production of ROS was detected by fluorescence probe 
2’,7’-dichlorofluorescin diacetate (DCFH-DA, Sigma-Aldrich) as previously 
described [29]. Briefly, after treatment, cells were washed three times with PBS and 
then incubated in 10 μM DCFH-DA for 30 min at 37 °C for green fluorescent light 
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visualization. Quantification of green fluorescence was analyzed by using ImageJ 
(Version 1.48, National Institutes of Health, Bethesda, MD). 
 
2.6. RNA extraction and quantitative PCR 
Total RNA of cells was extracted by using illustra
TM
 RNAspin mini kit (GE 
healthcare, UK). The preparation of the first-strand cDNA was conducted following 
the instruction of the SuperScript
TM
 First-Strand Synthesis System (Invitrogen, 
Calsbad, CA). The mRNA expression levels of target genes were measured by Takara 
SYBR premix Taq quantitative PCR system (Takara Bio Inc, Shiga, Japan) and in 
MyiQ2 real-time PCR machine (Bio-Rad). Parallel amplification of 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the internal 
control. Relative quantification was done by using the 2
-ΔΔCt
 method. The relative 
expression of the specific gene to the internal control was obtained and then expressed 
as percentage of the control value. All real-time PCR procedures including the design 
of primers, validation of PCR environment and quantification methods were 
performed according the MIQE guideline [30]. 
 
2.7. Western blot 
Western blot analyses of cell lysates were performed as described [31]. The ratio 
of the optical density of the protein product to the internal control (β-actin) was 
obtained and was expressed as ratio or percentage of the control value in the Figures. 
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2.8. ELISA assay 
ELISA measurements of secreted TNF-α, IL-1β, and IL-6 were performed by 
using corresponding ELISA development kits from PeproTech (PeproTech Inc., 
Rocky Hill, NJ) according to user instructions. ELISA assay kit for secreted IL-18 
was purchased from Invitrogen. 
 
2.9. Statistical analysis 
Data from each group were expressed as means ± SEM. Statistical comparison 
between groups was done using the Kruskal–Wallis test followed by Dunn’s post hoc 
test to detect differences in all groups. A p < 0.05 was considered to be statistically 
significant (Prism 5.0, Graphpad software, Inc., San Diego, CA). 
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3. Results 
3.1. LBP alleviated cellular injury, apoptosis, inflammation and oxidative stress in 
BRL-3A cells 
    After 24 and 48 hrs incubation with ethanol, the viability of BRL-3A cells 
decreased in a dose-dependent manner. However, there was a significant change 
between control and ethanol-treated group only when the dose of ethanol was higher 
than 50 mM (Figs. 1A and 1B). Interestingly, the decreasing levels of each ethanol 
dose between 24-hr and 48-hr treatment were quite similar, indicating that the 
damaging effects of ethanol on BRL-3A cells primarily occurred in the first 24 hrs 
(Figs. 1A and 1B). Therefore, in order to induce evident alcoholic cellular injury, we 
chose 250 mM as the treatment dose and 24 hrs as the duration in the following 
experiments.  
    To find out the optimal dose of LBP treatment, different doses (0 - 500 μg/ml) 
prior to the ethanol incubation were applied. Results showed that 50, 100, and 500 
μg/ml of LBP recovered the cell viability to control-comparable levels (Fig. 1C). Thus, 
we selected 50 μg/ml as the treating dose of LBP in the following studies. 
    Since apoptosis is a direct consequence of ethanol-induced hepatic damage, we 
firstly measured the change of BRL-3A cellular apoptotic ratio after ethanol exposure 
in the absence or presence of LBP pre-treatment. It was exhibited that ethanol 
incubation significantly increased the apoptotic ratio from ~3% to ~25% (p < 0.05), 
which was attenuated by the LBP treatment (from ~25% to ~18%, p < 0.05). Vehicle 
LBP treatment did not influence the cell apoptosis (Fig. 1D). Then we measured the 
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secretion protein level of pro-inflammatory cytokines TNF-α and IL-6 in the medium. 
Similar to the change of apoptotic ratio, ethanol significantly increased the secretion 
of both TNF-α and IL-6 from BRL-3A cells, indicating an inflammatory status of the 
cells (Figs. 1E and 1F). Pre-treatment with LBP reduced the cytokine levels without 
influencing their basal secretions (Figs. 1E and 1F). 
To further investigate the involvement of oxidative stress in the ethanol-induced 
damage, we stained the production of cellular ROS after ethanol incubation with or 
without LBP pre-treatment. It was found that ethanol obviously increased the signal of 
ROS staining, while LBP slightly reduced it (Fig. 1G). This phenomenon was in line 
with the antioxidant enzymes' result, in which the cellular level of CAT and GPx1 was 
significantly down-regulated by ethanol incubation but recovered by the pre-treatment 
with LBP (Figs. 1H and 1I). We also found that the cellular protein level of TXNIP 
was positively correlated with the production of ROS (Fig. 1J). All these data 
indicated that pre-treatment with 50 μg/ml LBP attenuated ethanol-induced cellular 
injury, apoptosis, inflammation and oxidative stress in BRL-3A cells. 
 
* Figure 1 here * 
 
3.2. LBP inhibited NLRP3 inflammasome activation after ethanol exposure 
To characterize the involvement of NLRP3 in ethanol-induced hepatocyte 
damage and LBP-mediated protection, secreted protein levels of both IL-1β and IL-18 
were measured by ELISA in all groups. It was shown that ethanol significantly 
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increased the secretion of both proteins and LBP counteracted such effects without 
affecting their basal levels (Figs. 2A and 2B). Then the cellular contents of key 
NLRP3 inflammasome components, including NLRP3, ASC and caspase-1 were 
examined by Western blot. Results exhibited that 24-hr ethanol incubation 
significantly up-regulated their protein levels, indicating that NLRP3 inflammasome 
was activated during ethanol incubation (Figs. 2C-2E). Pre-treatment with LBP 
significantly reduced their levels (Figs. 2C-2E). 
 
* Figure 2 here * 
 
3.3. LBP alleviated NLRP3 inflammasome in a TXNIP-dependent manner 
To verify that the inhibition of NLRP3 inflammasome was due to the 
down-regulation of TXNIP, BRL-3A cells were transfected with TXNIP siRNA for 48 
hrs and then incubated with ethanol and/or LBP. We found that siRNA against TXNIP 
successfully inhibited its endogenous expression, verified by quantitative PCR assay 
(Fig. 3A). TXNIP silencing prevented ethanol-induced cellular apoptosis, TNF-α, and 
ROS production in BRL-3A cells, indicating that hepatic TXNIP may mediate the 
activation of cellular injury pathways in ethanol-exposed cells (Figs. 3B-3D). 
Addition of LBP did not pose further influence in this cell model (Figs. 3B-3D). 
Control siRNA did not influence the cellular phenotypes affected by ethanol (data not 
shown). 
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* Figure 3 here * 
 
Then the secretion of IL-1β and IL-18, as well as the cellular protein content of 
NLRP-3, ASC and caspase-1 were measured. Consistent with the change of apoptotic 
ratio and TNF-α secretion, inhibition of TXNIP significantly decreased the elevated 
contents, either cellular or secreted, of all these proteins after ethanol exposure. 
Pre-treated LBP prior to ethanol incubation did not further affect the effects of TXNIP 
on these markers (Fig. 4). These data confirmed that TXNIP mediated the 
amelioration of hepatic injury by LBP pre-treatment under ethanol-exposure 
condition. 
 
* Figure 4 here * 
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4. Discussion 
    The hepatoprotective roles of LBP have been extensively studied in the past 
decade. In chemical-induced acute liver injury model and high-fat diet-induced 
NAFLD model, LBP is shown to attenuate hepatic disorders, including histological 
changes, lipid deposition, oxidative stress, inflammation, and apoptosis [32, 33]. For 
ALD, only one study indicating that, in a rat AFLD model, co-treatment with 300 
mg/kg LBP significantly ameliorated liver injury, prevented the progression of 
alcohol-induced fatty liver, and improved the antioxidant functions when compared 
with the ethanol group [34]. However, the detailed protective mechanisms were still 
unknown. Here we firstly showed that pre-treatment with 50 μg/ml LBP significantly 
attenuated ethanol-induced hepatocyte damages, including cell death, apoptosis, 
inflammation and oxidative stress. Then the involvement of TXNIP and NLRP3 
inflammasome in the protection of LBP against ethanol was demonstrated, which was 
consistent with its potent antioxidant and anti-inflammatory properties reported by 
previous studies [35, 36]. 
    To date, little is known about the role of NLRP3 inflammasome in ALD. It is 
already documented that serum levels of IL-1β were increased in both alcoholics and 
experimental animal model [37, 38]. Also, in HepG2 cells treated with acetaldehyde, a 
metabolic product of alcohol, the secretion level of both IL-1β and TNF-α was 
increased [39]. Recently, in a mouse model of chronic alcohol feeding, activated 
NLRP3 inflammasome components (NLRP3, ASC, and pro-caspase-1) as well as 
increased serum and liver mature IL-1β were observed, suggesting that inflammasome 
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activation is an pathogenic event in ALD [40]. In this study, we demonstrated that 
after ethanol incubation, the secretion of pro-inflammatory cytokines was increased in 
parallel with the activation of NLRP3 inflammasome, further confirmed the 
involvement of this kind of inflammasome in ethanol-induced hepatic injury. Addition 
of LBP counteracted such effects from ethanol. 
As (1) oxidative damage is an event predominantly in hepatocytes following 
alcohol administration and (2) increased oxidative stress may promote cellular 
inflammation and apoptosis, applying antioxidant compounds to protect against the 
liver injury is rational [41]. Under hyperglycemia, over-expressed TXNIP switches 
the function of TXNIP from TRX repressor to NLRP3 inﬂammasome activator [42]. 
Recently, TXNIP was further confirmed to directly activate NLRP3 inﬂammasome 
upon oxidative stress [23]. In addition, activated NLRP3 induces caspase-1 
hyperactivity, which cleaved the precursor forms of IL-1β and IL-18 to increase the 
inflammatory responses in the liver [43]. Therefore, regulating the expression of 
TXNIP may be an effective way to inhibit the hepatic inflammation through 
attenuating NLRP3 activation. In the current in vitro study, LBP administration 
significantly reduced the expression NLRP3 inflammasome complex and ROS 
production upon ethanol exposure. Silence of endogenous TXNIP expression blocked 
those events, as well as hepatic injuries including apoptosis and oxidative stress, 
confirming the essential role of TXNIP in the induction of NLRP3 inflammasome and 
the possible mechanistic pathway of LBP protection. 
In conclusion, LBP attenuated ethanol-induced hepatic damages through 
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suppressing the activation of NLRP3 inflammasome in a TXNIP-dependent manner in 
the BRL-3A in vitro system. These results further supported evidence that inhibition 
of hepatic TXNIP-NLRP3 inflammasome axis contributes to the alleviation of hepatic 
injury caused by ethanol. This axis may provide a novel therapeutic target of ALD. 
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Figure legends 
Fig. 1. Effects of LBP on ethanol-induced hepatic injury. (A, B) BRL-3A cells were 
treated by 0, 1, 10, 50, 100, 250, 500 and 1000 mM ethanol for 24 hrs or 48 hrs. Cell 
viability after ethanol exposure was measured by MTT assay. (C) BRL-3A cells were 
treated by 250 mM with pre-treatment with 0, 1, 10, 50, 100 and 500 μg/ml LBP for 
24 hrs. Cell viability after ethanol exposure was measured by MTT assay. To test the 
effects of LBP on 24-hr ethanol-induced hepatic apoptosis and inflammation, (D) 
apoptotic ratio, (E) secreted TNF-α content, and (F) secreted IL-6 content were 
measured by Hoechst 33342/propidium iodide and ELISA, respectively. (G) The 
panel shows the fluorescent image stained DCFH-DA for the measurement of ROS 
production in BRL-3A cells (magnification, x200). Quantified green fluorescence 
values were analyzed by ImageJ. To verify the oxidative stress change after LBP and 
ethanol treatments, protein expression of (H) CAT, (I) GPx1, and (J) TXNIP was 
measured by Western blot. Data from each group (n = 5) were expressed as 
means ± SEM. Statistical comparison between groups was done using the 
Kruskal–Wallis test followed by Dunn’s post hoc test to detect differences in all 
groups. A p < 0.05 was considered to be statistically significant and showed as 
different letters (e.g. a and b). EtOH, ethanol; v-LBP, vehicle LBP; E+L, ethanol with 
LBP pre-treatment. 
 
Fig. 2. Effects of 50 μg/ml LBP on 24-hr ethanol-induced activation of NLRP3 
inflammasome. Change of secreted protein content of (A) IL-1β and (B) IL-18 was 
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measured by ELISA in BRL-3A cells. Then the change of protein level of (C) NLRP3, 
(D) ASC, and (E) caspase-1 was measured by Western blot in BRL-3A cells. Data 
from each group (n = 5) were expressed as means ± SEM. Statistical comparison 
between groups was done using the Kruskal–Wallis test followed by Dunn’s post hoc 
test to detect differences in all groups. A p < 0.05 was considered to be statistically 
significant and showed as different letters (e.g. a and b). EtOH, ethanol; v-LBP, 
vehicle LBP; E+L, ethanol with LBP pre-treatment. 
 
Fig. 3. Influence of TXNIP silence on 24-hr ethanol-induced hepatic apoptosis, 
inflammation and ROS production in BRL-3A cells. (A) The panel shows the 
efficiency of siRNA against TXNIP, when compared with the control siRNA, on 
endogenous TXNIP mRNA expression. Then the change of (B) apoptotic ratio, (C) 
secreted TNF-α content, and (D) ROS production was measured by Hoechst 
33342/propidium iodide, ELISA, and DCFH-DA staining (magnification, x200), 
respectively. Quantified green fluorescence values were analyzed by ImageJ. Data 
from each group (n = 5) were expressed as means ± SEM. Statistical comparison 
between groups was done using the Kruskal–Wallis test followed by Dunn’s post hoc 
test to detect differences in all groups. A p < 0.05 was considered to be statistically 
significant and showed as different letters (e.g. a and b). 
 
Fig. 4. Influence of TXNIP silence on 24-hr ethanol-induced activation of NLRP3 
inflammasome. Change of secreted protein content of (A) IL-1β and (B) IL-18 was 
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measured by ELISA in BRL-3A cells. Then the change of protein level of (C) NLRP3, 
(D) ASC, and (E) caspase-1 was measured by Western blot in BRL-3A cells. Data 
from each group (n = 5) were expressed as means ± SEM. Statistical comparison 
between groups was done using the Kruskal–Wallis test followed by Dunn’s post hoc 
test to detect differences in all groups. A p < 0.05 was considered to be statistically 
significant and showed as different letters (e.g. a and b). 
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Table 1. Sequences of TXNIP siRNA and PCR primers. 
Name Sequence 
Rat TXNIP siRNA 
s: 5’-GCUGGAUAGACCUAAACAUTT-3’ 
as: 5’-AUGUUUAGGUCUAUCCAGCTT-3’ 
Control siRNA 
s: 5’-UUCUCCGAACGUGUCACGUTT-3’ 
as: 5’-ACGUGACACGUUCGGAGAATT-3’ 
Rat TXNIP mRNA 
s: 5’-TAGTGTCCCTGGCTCCAAGAAA-3’ 
as: 5’-GGATGTTTAGGTCTATCCAGCTCAT-3’ 
Rat GAPDH 
s: 5’-AGGTCGGTGTGAACGGATTTG-3’ 
as: 5’-TGTAGACCATGTAGTTGAGGTCA-3’ 
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